| Symbol | BETRF |
|---|---|
| Name | BETTERLIFE PHARMA INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | V6H 1A6 Canada BC 1275 WEST 6TH AVENUE #300 |
| Telephone | 604-805-7783 |
| Fax | — |
| — | |
| Website | https://abetterlifepharma.com/ |
| Incorporation | CA |
| Incorporated On | 2002 |
| Employees | — |
| Fiscal Year | 1/31 |
| Public Since | — |
| Exchanges | OTC;NASDAQ |
| Auditor | MNP LLP; |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0001464165 |
| Description | BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. Additional info from OTC: |
BetterLife Pharma Inc. Announces Pricing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
Read moreBetterLife Pharma Inc. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
Read moreBetterLife Pharma Appoints Mahan Chehrenama, DO, as Chief Medical Officer
Read moreBetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism
Read moreBetterLife Pharma Announces Appointment of John W. LaRocca to Board of Directors and Audit Committee
Read moreBetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1
Read moreBetterLife Pharma Announces Issuance of Shares and Extension of Convertible Debentures
Read moreBetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director
Read moreBetterLife Pharma Announces Intent to Complete CAD $2 Million in Convertible Debenture to Complete BETR-001 IND Filing
Read more